Answers are grounded in this paper and cite their sources.
AIMS: To determine whether frequency of tobacco, cannabis and binge alcohol use in the 12 months prior to SARS-CoV-2 test result or COVID-19 symptom onset is associated with (1) presence of symptomatic Long COVID at study entry and (2) development of symptomatic Long COVID over 12 months of follow-up, among those without Long COVID at study entry. DESIGN: Prospective cohort study with cross-sectional and longitudinal components. SETTING: Multi-site study conducted across 83 clinical sites in the United States. PARTICIPANTS: A total of 9477 adults enrolled between October 2021 and July 2024 (median age 43 years; 74% female). MEASUREMENTS: Self-reported frequency of tobacco product, cannabis and binge alcohol use in the 12 months prior to SARS-CoV-2 test infection (never, monthly or less, weekly or none). Symptomatic Long COVID was defined using the Researching COVID to Enhance Recovery (RECOVER)-Adult Long COVID Research Index, with scores ≥ 11 classified as symptomatic Long COVID and lower scores classified as indeterminate. Covariates included sociodemographic characteristics, clinical comorbidities and COVID-19 related factors. RESULTS: At study entry 20% of participants met criteria for symptomatic Long COVID. In the 12 months preceding infection, 14%, 21% and 38% reported any tobacco product, cannabis or binge alcohol use. At study entry, compared with no use, weekly or more tobacco use was associated with higher odds of symptomatic Long COVID [adjusted odds ratio (aOR) = 1.37, 95% confidence interval (CI) = 1.13-1.67]; weekly or more cannabis use was associated with higher odds of symptomatic Long COVID (aOR = 1.23, 95% CI = 1.00-1.52); and weekly or more binge alcohol use was associated with lower odds (aOR = 0.73, 95% CI = 0.58-0.91) of symptomatic Long COVID. Monthly or less use of any substance was not associated with symptomatic Long COVID at study entry. Among participants without symptomatic Long COVID at study entry, weekly or more tobacco use, compared with no use, was associated with higher odds of developing symptomatic Long COVID over 12 months of follow-up (aOR = 1.29, 95% CI = 1.03-1.62). Neither cannabis nor binge alcohol use was statistically significantly associated with symptomatic Long COVID at 12-month follow-up. SUMMARY: Among adult participants of the Researching COVID to Enhance Recovery (RECOVER) study, weekly or more tobacco use in the 12 months prior to SARS-CoV-2 infection was associated with higher odds of symptomatic Long COVID at study entry and at 12 months among participants who did not meet criteria for symptomatic Long COVID at study entry. Weekly or more cannabis use was associated with higher odds of symptomatic Long COVID at study entry and was not associated with symptomatic Long COVID at 12 months. Weekly or more binge alcohol use was associated with lower odds of symptomatic Long COVID at study entry and was not associated with symptomatic Long COVID at 12 months.
No takes yet. Share an insight, caveat, or question.
Okafor et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: